Scientific Program

Conference Series Ltd invites all the participants across the globe to attend International Conference on Obesity, Diet Management & Nutrition Venue & Hospitality : Hilton New York JFK Airport Hotel in March 18 - 19, 2019 New York, USA.

Day 2 :

OMICS International Obesity 2019 International Conference Keynote Speaker John Ebnezar photo
Biography:

Dr. John Ebnezar is an internationally renowned orthopedic surgeon, passionate about creating, conceptualizing, implementing preventive new orthopedic health awareness modules with an aim to propagate low cost orthopedic health care. He is specialized in trauma, spine, geriatric orthopedics and sports medicine. He holds Guinness World Records both for academics and social service, only orthopedic surgeon in the world to do so. He is a PhD in yoga, involved in 6 original-yoga researches, won Best Research Award from SVyasa Yoga University (2012) for his work on knee arthritis and role of Yoga in fracture healing (2010). He has pioneered a new treatment method, Wholistic Orthopedics, by blending modern orthopedics with Indian Yoga, which is simple, cheap, effective alternative method of treating all varieties of OA knees and also for patients with modern life style orthopedic problems and has redefined the way orthopedic ailments are treated across the globe.

Abstract:

OMICS International Obesity 2019 International Conference Keynote Speaker Young Jin Tak photo
Biography:

Recent animal studies found the potential that collagen peptide derived from skate skin have anti-obesity effects through suppression of fat accumulation and regulation of lipid metabolism. However, no studies have yet been performed in human. Here, this very first human study randomized, placebo-controlled, and double-blinded was designed to investigate the efficacy and tolerability of skate skin collagen peptides (SCP) for reduction of body fat in overweight adults. Ninety healthy volunteers (17 men) aged 41.2 ± 10.4 years with mean body mass index of 25.6 ± 1.9 kg/m2 were assigned to the intervention group (IG) which received 2,000 mg of SCP per day or to the control group (CG) given placebo for 12 weeks and 81 (90%) participants completed the study. Changes in body fat were evaluated using dual energy X-ray absorptiometry as a primary efficacy endpoint. After 12 weeks of trial, the percentage of body fat and body fat mass (kg) in IG were found to be significantly better than those of subjects in CG (-1.2% vs. 2.7%, p=0.024 and -1.2 kg vs. 0.3 kg, p=0.025). Application of SCP was well tolerated, and no notable adverse effect was reported from both groups. These results suggest the beneficial potential of SCP in reduction of body fat in overweight adults.

Abstract: